238 related articles for article (PubMed ID: 16611058)
21. A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children.
Persaud D; Pierson T; Ruff C; Finzi D; Chadwick KR; Margolick JB; Ruff A; Hutton N; Ray S; Siliciano RF
J Clin Invest; 2000 Apr; 105(7):995-1003. PubMed ID: 10749578
[TBL] [Abstract][Full Text] [Related]
22. Peering into the HIV reservoir.
García M; Buzón MJ; Benito JM; Rallón N
Rev Med Virol; 2018 Jul; 28(4):e1981. PubMed ID: 29744964
[TBL] [Abstract][Full Text] [Related]
23. A reservoir for HIV in patients on combination antiretroviral therapy.
Siliciano RF
Hopkins HIV Rep; 1998 Jan; 10(1):1, 5-6, 11. PubMed ID: 11365130
[TBL] [Abstract][Full Text] [Related]
24. Viral reservoirs, residual viremia, and the potential of highly active antiretroviral therapy to eradicate HIV infection.
Shen L; Siliciano RF
J Allergy Clin Immunol; 2008 Jul; 122(1):22-8. PubMed ID: 18602567
[TBL] [Abstract][Full Text] [Related]
25. Reservoirs of HIV replication after successful combined antiretroviral treatment.
Belmonte L; Baré P; de Bracco MM; Ruibal-Ares BH
Curr Med Chem; 2003 Feb; 10(4):303-12. PubMed ID: 12570703
[TBL] [Abstract][Full Text] [Related]
26. Paucity of Intact Non-Induced Provirus with Early, Long-Term Antiretroviral Therapy of Perinatal HIV Infection.
Rainwater-Lovett K; Ziemniak C; Watson D; Luzuriaga K; Siberry G; Petru A; Chen Y; Uprety P; McManus M; Ho YC; Lamers SL; Persaud D
PLoS One; 2017; 12(2):e0170548. PubMed ID: 28178277
[TBL] [Abstract][Full Text] [Related]
27. Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study.
Routy JP; Tremblay CL; Angel JB; Trottier B; Rouleau D; Baril JG; Harris M; Trottier S; Singer J; Chomont N; Sékaly RP; Boulassel MR
HIV Med; 2012 May; 13(5):291-6. PubMed ID: 22276680
[TBL] [Abstract][Full Text] [Related]
28. A novel assay allows genotyping of the latent reservoir for human immunodeficiency virus type 1 in the resting CD4+ T cells of viremic patients.
Monie D; Simmons RP; Nettles RE; Kieffer TL; Zhou Y; Zhang H; Karmon S; Ingersoll R; Chadwick K; Zhang H; Margolick JB; Quinn TC; Ray SC; Wind-Rotolo M; Miller M; Persaud D; Siliciano RF
J Virol; 2005 Apr; 79(8):5185-202. PubMed ID: 15795302
[TBL] [Abstract][Full Text] [Related]
29. Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.
Olesen R; Vigano S; Rasmussen TA; Søgaard OS; Ouyang Z; Buzon M; Bashirova A; Carrington M; Palmer S; Brinkmann CR; Yu XG; Østergaard L; Tolstrup M; Lichterfeld M
J Virol; 2015 Oct; 89(20):10176-89. PubMed ID: 26223643
[TBL] [Abstract][Full Text] [Related]
30. Reconstitution of EBV latent but not lytic antigen-specific CD4+ and CD8+ T cells after HIV treatment with highly active antiretroviral therapy.
Piriou E; Jansen CA; van Dort K; De Cuyper I; Nanlohy NM; Lange JM; van Oers MH; Miedema F; van Baarle D
J Immunol; 2005 Aug; 175(3):2010-7. PubMed ID: 16034146
[TBL] [Abstract][Full Text] [Related]
31. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
32. Reservoirs of human immunodeficiency virus type 1: the main obstacles to viral eradication.
Pomerantz RJ
Clin Infect Dis; 2002 Jan; 34(1):91-7. PubMed ID: 11731950
[TBL] [Abstract][Full Text] [Related]
33. Latent reservoirs of HIV: obstacles to the eradication of virus.
Chun TW; Fauci AS
Proc Natl Acad Sci U S A; 1999 Sep; 96(20):10958-61. PubMed ID: 10500107
[TBL] [Abstract][Full Text] [Related]
34. HIV reservoir dynamics in the face of highly active antiretroviral therapy.
Costiniuk CT; Jenabian MA
AIDS Patient Care STDS; 2015 Feb; 29(2):55-68. PubMed ID: 25412339
[TBL] [Abstract][Full Text] [Related]
35. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy.
Saksena NK; Potter SJ
AIDS Rev; 2003; 5(1):3-18. PubMed ID: 12875103
[TBL] [Abstract][Full Text] [Related]
36. Scientific rationale for antiretroviral therapy in 2005: viral reservoirs and resistance evolution.
Siliciano RF
Top HIV Med; 2005; 13(3):96-100. PubMed ID: 16170226
[TBL] [Abstract][Full Text] [Related]
37. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of human immunodeficiency virus type 1-infected patients on highly active antiretroviral therapy.
Shen A; Zink MC; Mankowski JL; Chadwick K; Margolick JB; Carruth LM; Li M; Clements JE; Siliciano RF
J Virol; 2003 Apr; 77(8):4938-49. PubMed ID: 12663799
[TBL] [Abstract][Full Text] [Related]
38. Extracellular vesicle-mediated intercellular communication in HIV-1 infection and its role in the reservoir maintenance.
Olivetta E; Chiozzini C; Arenaccio C; Manfredi F; Ferrantelli F; Federico M
Cytokine Growth Factor Rev; 2020 Feb; 51():40-48. PubMed ID: 31926807
[TBL] [Abstract][Full Text] [Related]
39. Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppressive Combined Antiretroviral Therapy.
Liu B; Zou F; Lu L; Chen C; He D; Zhang X; Tang X; Liu C; Li L; Zhang H
J Virol; 2016 Nov; 90(21):9712-9724. PubMed ID: 27535056
[TBL] [Abstract][Full Text] [Related]
40. LGIT In Vitro Latency Model in Primary and T Cell Lines to Test HIV-1 Reactivation Compounds.
Jung U; Takahashi M; Rossi JJ; Burnett JC
Methods Mol Biol; 2016; 1354():255-64. PubMed ID: 26714717
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
